Charles Schwab Investment Management Inc. increased its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 238.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 911,617 shares of the company's stock after buying an additional 642,259 shares during the period. Charles Schwab Investment Management Inc. owned about 0.55% of Savara worth $3,865,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also made changes to their positions in the business. Intech Investment Management LLC acquired a new position in shares of Savara during the third quarter worth $174,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Savara by 54.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 690,609 shares of the company's stock worth $2,928,000 after purchasing an additional 242,249 shares in the last quarter. Jennison Associates LLC increased its position in shares of Savara by 17.5% during the third quarter. Jennison Associates LLC now owns 6,732,776 shares of the company's stock worth $28,547,000 after purchasing an additional 1,001,296 shares in the last quarter. LMR Partners LLP increased its position in shares of Savara by 138.3% during the third quarter. LMR Partners LLP now owns 36,800 shares of the company's stock worth $156,000 after purchasing an additional 132,900 shares in the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in shares of Savara by 14.8% during the third quarter. Oppenheimer & Co. Inc. now owns 115,604 shares of the company's stock worth $490,000 after purchasing an additional 14,867 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.
Savara Stock Performance
NASDAQ:SVRA traded down $0.14 during mid-day trading on Friday, hitting $3.21. The company's stock had a trading volume of 3,170,820 shares, compared to its average volume of 1,278,070. Savara Inc has a 1 year low of $2.82 and a 1 year high of $5.70. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The stock has a market cap of $550.90 million, a price-to-earnings ratio of -7.47 and a beta of 0.92. The business's fifty day moving average is $3.52 and its two-hundred day moving average is $4.02.
Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). Analysts anticipate that Savara Inc will post -0.45 EPS for the current fiscal year.
Insider Buying and Selling at Savara
In other news, Director Joseph S. Mccracken bought 20,000 shares of the stock in a transaction dated Tuesday, November 19th. The shares were acquired at an average cost of $2.95 per share, with a total value of $59,000.00. Following the purchase, the director now directly owns 210,837 shares in the company, valued at $621,969.15. The trade was a 10.48 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.13% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the stock. Evercore ISI reissued an "in-line" rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a report on Wednesday, November 13th. JMP Securities reissued a "market outperform" rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright dropped their price objective on shares of Savara from $10.00 to $6.00 and set a "buy" rating on the stock in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $10.17.
View Our Latest Stock Analysis on Savara
Savara Profile
(
Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Stories
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
